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Crosstalk between PXR and CAR. A multitude of xeno-
biotics can interact with PXR or CAR or both. Ligand 
binding leads to the translocation of the receptor from 
the cytoplasm to the nucleus, where both PXR and 
CAR use the retinoic X receptor (RXR) as a partner 
for heterodimerization and bind to corresponding cis-
acting elements of their target genes. PXR and CAR 
mediate gene regulation through certain direct repeats, 
known as the PXR responsive element (PXRRE) and 
the PB responsive element module (PBREM). Target 
genes that contain PXRREs and PBREMs in their 
promoters can be regulated both by PXR and CAR. 
Among those that are subject to PXR and CAR regula-
tion are a number of genes encoding phase I or phase 
II drug-metabolizing enzymes or transporters. UGT, 
uridine diphosphate-glucuronosyltransferase; SULT, 
sulfotransferase; GST, glutathione S-transferase.
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Strategy to generate huPXR, huCAR, 
and KO mice. (A) PXR: An hPXR 
minigene containing a fusion of exons 
2–4, intron 4, exon 5, intron 5, and a 
fusion of exons 6–9 was knocked in 
onto the translational start ATG of 
the mPxr WT gene in order to gen-
erate PXR-targeted mice. (B) CAR: 
The coding region of the mCar WT 
gene was replaced with the genomic 
coding region of hCAR, including 
exons 2–9, in order to generate 
CAR-targeted mice. In both cases, 
mouse exons are indicated in black 
and with lower-case letters; human 
exons are indicated in white and 
with upper-case letters. Targeted 
mice are crossed to a mouse strain 
expressing the FLPe recombinase to 
delete the hygromycin or neomycin 
selection cassette, respectively, and 
to generate huPXR or huCAR mice 
or to a φC31 deleter strain to gener-
ate PXR or CAR KO mice. For the 
sake of clarity, sequences of the tar-
geting vector are not drawn to scale.
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Relevance of PXR and CAR for the induction of Cyp3a11 and Cyp2b10 








































hPXR, mPXR, hCAR, and mCAR mRNA expression. RNA was iso-
lated from untreated WT (n = 27), huPXR (n = 9), huCAR (n = 13), and 
huPXR/huCAR (n = 13) mice. mPXR, hPXR, hCAR, and mCAR mRNA 
expression was analyzed by qPCR (TaqMan) in the liver (A) and small 
intestine (B). Values represent mean ΔCt values (Ct values for each 
gene of interest normalized to the Ct values for the internal standard 
β-actin) for all mice/genotypes. Error bars indicate SD in ΔCT values 
between animals of the same genotype.
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In order  to evaluate  the  interaction of 
compounds with hCAR or hPXR in vitro, 
transactivation assays are routinely used 
(reviewed  in  ref.  6).  The most  common 



























Isoforms corresponding to known human splice 
variants detected in the (A) huPXR and (B) huCAR 
mouse. Exons are presented as white (mouse) or 
dark gray (human) boxes. Deleted parts of exons 
are indicated as light gray, inserted parts as black 
boxes. The different isoforms are denominated 
according to their names in previous publications 
(19, 22). In all cases, the noncoding exon 1 is of 
mouse origin. In both huPXR and huCAR mice, fur-
ther and yet unidentified splice variants presumably 
coding for nonfunctional receptors were detected 
at low abundance (not shown). DBD, DNA-binding 
domain; SV1-9, splice variants 1–9.
Figure 5
PXR-dependent induction of Cyp3a11 by RIF. (A) Pooled liver microsomes from huPXR, PXR 
KO, and WT mice (n = 3) treated with either RIF or the vehicle were analyzed for Cyp3a11 
and Cyp2b10 expression by immunoblotting. 5 μg protein was loaded onto a 7.5% SDS-PAGE 
gel, and membranes were incubated with polyclonal Cyp3a11 and Cyp2b10 antibodies. (B) 
BQ assays were performed to investigate Cyp3a activity in pooled WT or huPXR mouse liver 
microsomes. Values are expressed as mean ± SD. n = 3 mice for all experiments.
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PXR-dependent induction of Cyp3a11 by dexamethasone. 
(A and B) Pooled liver microsomes from huPXR, PXR 
KO, and WT mice (n = 3) treated with either DEX or 
the vehicle were analyzed for Cyp3a11 and Cyp2b10 
by immunoblotting. 5 μg protein was loaded onto a 
7.5% SDS-PAGE gel, and membranes were incu-
bated with polyclonal Cyp3a11 and Cyp2b10 anti-
bodies. (C) BQ and PROD assays were performed to 
investigate Cyp3a and Cyp2b activities, respectively, 
in pooled WT, huPXR, or PXR KO mouse liver micro-
somes (n = 3 mice). Values are expressed as mean 
± SD; n = 3 mice for all experiments. Student’s t test 
(2-sided) was performed on the results. *P < 0.05; 
**P < 0.01; ***P < 0.001, statistically different from 
control. +ve, His-tagged mouse Cyp2b10 or Cyp3a11 
recombinant proteins.
Figure 7
CAR-dependent induction of Cyp2b10 by CITCO. (A and B) Pooled 
liver microsomes from huCAR, CAR KO, PXR KO, huPXR, and WT 
mice (n = 3) treated with either CITCO or vehicle were analyzed for 
Cyp2b10 and Cyp3a11 expression by immunoblotting. 5 μg protein 
was loaded onto a 7.5% SDS-PAGE gel, and membranes were incu-
bated with polyclonal Cyp2b10 or Cyp3a11 antibodies. (C) PROD 
assays were performed to investigate Cyp2b activity in pooled WT or 
huCAR mouse liver microsomes (n = 3 mice). Values are expressed 
as mean ± SD; n = 3 mice for all experiments. Student’s t test (2-sided) 
was performed. *P < 0.05; **P < 0.01; ***P < 0.001, statistically dif-
ferent from control.
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CAR-dependent induction of Cyp2b10 by TCPOBOP. (A and B) Pooled 
liver microsomes from huCAR, CAR KO, PXR KO, and WT mice (n = 3) 
treated with either TCPOBOP or vehicle were analyzed for Cyp2b10 
and Cyp3a11 expression by immunoblotting. 5 μg protein was loaded 
onto a 7.5% SDS-PAGE gel, and membranes were incubated with 
polyclonal Cyp2b10 and Cyp3a11 antibodies. (C) PROD assays were 
performed to investigate Cyp2b activity in pooled WT or huCAR mouse 
liver microsomes (n = 3). Values are expressed as mean ± SD; n = 3 
mice for all experiments. Student’s t test (2-sided) was performed. 
*P < 0.05; **P < 0.01; ***P < 0.001, statistically different from control.
Figure 9
CAR-dependent induction of 
Cyp2b10 and Cyp3a11 by PB. 
(A) Pooled liver microsomes from 
huPXR, PXR KO, huCAR, CAR 
KO, huPXR/huCAR, PXR KO/
CAR KO, huPXR/CAR KO, PXR 
KO/huCAR, and WT mice (n = 3) 
treated with either PB or vehicle 
were analyzed for Cyp2b10 and 
Cyp3a11 expression by immunob-
lotting. 5 μg protein was loaded 
onto a 7.5% SDS-PAGE gel, and 
membranes were incubated with 
polyclonal Cyp2b10 and Cyp3a11 
antibodies. (B) PROD and BQ 
assays were performed to investi-
gate Cyp2b and Cyp3a activities, 
respectively, in pooled mouse liver 
microsomes from each mouse 
line indicated above (n = 3 mice). 
Values are expressed as mean ± 
SD; n = 3 mice for all experiments. 
Student’s t test (2-sided) was per-
formed. *P < 0.05; **P < 0.01; 
***P < 0.001, statistically different 
from control.
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PXR-  and CAR-mediated  effects  by uncovering  the  crosstalk 
between these 2 receptors and evaluating the significance of these 
Figure 10
Midazolam and bupropion pharmacokinetics in 
CITCO-treated WT and huCAR mice. (A) Midazolam 
and bupropion pharmacokinetics in WT and huCAR 
mice before (day 1) and after (day 5) treatment with 
10 mg/kg of 3 daily i.p. doses of CITCO. Values repre-
sent the concentration of parent drug in plasma (ng/ml) 
as mean of 4 mice. Error bars describe SD in either 
midazolam or bupropion plasma concentrations. (B) 
Ratios of the average midazolam and bupropion AUCs 
calculated from the corresponding pharmacokinetics 




PCR type Primers Expected fragment(s) Detected allele
PXR WT 5′-GCTTCTCATTTCTCCCTCCTG;  700 bp Detects WT mPxr	
	 5′-TGATCCTTTCCTGGGCAGC
hPXR 5′-GCTTCTCATTTCTCCCTCCTG;  386 bp Detects humanized PXR in both  
 5′-CTCCGACTTCCTCATCTGCG  FLP-deleted and -undeleted animals
PXR KO 5′-CCTCCTCACTACTCTCCCAGC;  1274 bp (WT) Detects φC31-mediated deletion of PXR 
 5′-GTACCAGCAAGTGCGTGAAGG 944 bp (KO) in KO mice (944 bp) and WT Pxr (1274 bp)
CAR WT 5′-CTCAACTCCTCCCACATTCAG;  663 bp Detects WT mCar	
	 5′-GCAAACGGACAGATGGGAC
hCAR 5′-CTCAACTCCTCCCACATTCAG;  369 bp Detects humanized CAR in both FLP-deleted 
 5′-TGCTCTTGACTAATGGGCTG   and -undeleted animals
CAR KO 5′-CTCAACTCCTCCCACATTCAG;  559 bp Detects φC31-mediated deletion of CAR in KO mice 
 5′-TCCCATCCCCTGTGTTTCC
PCR primers and primer combinations used to determine the genotypes of WT mice and mice modified at the Pxr and Car loci.
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from small  intestine using TRIzol  reagent  (Invitrogen) and from the 
liver using the QIAGEN RNA Mini Kit. cDNA was synthesized from 1 μg 
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total RNA using the Quantiscript Reverse Transcriptase Kit (QIAGEN). 
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